|
|
| (18 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | {{pnc}} | | {{pnc}} |
| | + | {{ft|P}} |
| | + | ...so calm down and enjoy the progress of immediate translational medicine: |
| | + | A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea. |
| | + | This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world |
| | + | vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents. |
| | + | Paper is (not yet in PubMed) : |
| | | | |
| − | current items will be put into the subsections.
| + | *'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]''' |
| | + | credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today. |
| | + | based on e.g. |
| | + | |
| | + | {{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}} |
| | + | |
| | + | ======================================================================================= |
| | + | |
| | + | COVID19 is now a CURABLE disease !!! |
| | + | |
| | + | ======================================================================================= |
| | | | |
| | *[[reviews on covid drug development]] | | *[[reviews on covid drug development]] |
| Zeile 26: |
Zeile 42: |
| | *[[Target Complement system]] | | *[[Target Complement system]] |
| | *[[Target Extracellular traps]] | | *[[Target Extracellular traps]] |
| | + | *[[Caplacizumab]] vWF(TTP) |
| | + | *[[Target Neurophils]] |
| | + | *[[Target Mast cells]] and kinins |
| | *[[TGF beta]] | | *[[TGF beta]] |
| | + | *[[Immunosuppressants]] |
| | *[[Anticoagulant in covid19]] | | *[[Anticoagulant in covid19]] |
| | *[[Antioxidants]] | | *[[Antioxidants]] |
| | + | *[[HIF-EPO-Iron]] |
| | *[[Stem cells]] | | *[[Stem cells]] |
| | *[[MDSC cells]] | | *[[MDSC cells]] |
| | *[[Interferons]] | | *[[Interferons]] |
| | + | *[[cAMP cGMP PDE NO]] |
| | + | *[[TRPV* channels]] |
| | + | *[[Retinoids]] |
| | + | *[[Protease inhibitors]] |
| | + | *[[Tyrosine kinase inhibitors]] |
| | + | *[[Antineoplastic agents, traditional]] |
| | + | *[[Mouthrinses]] |
| | + | *[[Adenosinergic signaling]] |
| | + | *[[Purinergic signaling]] |
| | + | *[[Nicotinergic signaling]] |
| | | | |
| | | | |
| | *[[other single compounds]] | | *[[other single compounds]] |
| − | *[[Retargeted single compounds]] | + | *[[Retargeted Psychopharm]] |
| | *[[Hydroxychloroquine]] | | *[[Hydroxychloroquine]] |
| | * | | * |
| | *[[Target ACE2, Spike protein]] | | *[[Target ACE2, Spike protein]] |
| | *[[Target TMPRSS2, Spike protein]] ''any other covid targed herein'' | | *[[Target TMPRSS2, Spike protein]] ''any other covid targed herein'' |
| | + | *[[Aprotinin]] protease inh bradykinin synth. inh. |
| | *[[other antiviral compounds]] | | *[[other antiviral compounds]] |
| | *[[AV Remdesivir]] | | *[[AV Remdesivir]] |
| Zeile 47: |
Zeile 79: |
| | *[[AV Favipiravir]] | | *[[AV Favipiravir]] |
| | | | |
| | + | *[[Antibiotics]] |
| | | | |
| | | | |
| Zeile 53: |
Zeile 86: |
| | *[[Anorganic nutrients Selenium]] | | *[[Anorganic nutrients Selenium]] |
| | *[[Anorganic nutrients Zinc]] | | *[[Anorganic nutrients Zinc]] |
| | + | *[[Anorganic nutrients Lithium]] |
| | + | *[[Anorganic nutrients Copper]] |
| | + | *[[Anorganic nutrients Bismuth]] |
| | *[[Nutrition, general]] | | *[[Nutrition, general]] |
| | *[[Exercise, Vibration]] | | *[[Exercise, Vibration]] |
| Zeile 63: |
Zeile 99: |
| | *[[Antidiabetic compounds, any]] | | *[[Antidiabetic compounds, any]] |
| | *[[RSP - On RAS drugs]] | | *[[RSP - On RAS drugs]] |
| | + | *[[RSP - On NSAIDs]] |
| | | | |
| | *[[Reconvalescent blood products, Passive vaccine]] | | *[[Reconvalescent blood products, Passive vaccine]] |
| Zeile 73: |
Zeile 110: |
| | | | |
| | *[[Treatment other concepts]] | | *[[Treatment other concepts]] |
| − | | + | ---- |
| − | ===-rest-===
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | ===009===
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32535032|t=2020. Vitamin D Receptor stimulation to reduce Acute Respiratory Distress Syndrome (ARDS) in patients with Coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32423449|t=2020. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32405423|t=2020. Minimum costs to manufacture new treatments for COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32405422|t=2020. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32405421|t=2020. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32401274|t=2020. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32501511|t=2020. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32530438|t=2020. New (re)Purpose for an old drug: purinergic receptor blockade may extinguish the COVID-19 thrombo-inflammatory firestorm.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32459647|t=2020. Intra-Rater and Inter-Rater Reliability of Tongue Coating Diagnosis in Traditional Chinese Medicine Using Smartphones: Quasi-Delphi Study.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32384188|t=2020. Parenteral Fish-Oil Emulsions in Critically Ill COVID-19 Emulsions.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32401715|t=2020. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32401712|t=2020. Interferon beta-1b for COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32410758|t=2020. Consider pregnancy in COVID-19 therapeutic drug and vaccine trials.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32464115|t=2020. Caution against corticosteroid-based COVID-19 treatment.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32445630|t=2020. Vitamin-D and COVID-19: do deficient risk a poorer outcome?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32501454|t=2020. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32518419|t=2020. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32528040|t=2020. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32535080|t=2020. Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32497632|t=2020. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32454157|t=2020. Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32450171|t=2020. Coronaviruses pandemics: Can neutralizing antibodies help?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32450166|t=2020. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M(pro) enzyme through in silico approach.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32422305|t=2020. Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32478465|t=2020. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32532461|t=2020. Eficacia de los pulsos de corticoides en pacientes con sindrome de liberacion de citocinas inducido por infeccion por SARS-CoV-2.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32416415|t=2020. Etoposide-based therapy for severe forms of COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32516655|t=2020. Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32504923|t=2020. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32485316|t=2020. Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32498007|t=2020. Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32492562|t=2020. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32480250|t=2020. Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32464491|t=2020. Selenium supplementation in the prevention of coronavirus infections (COVID-19).|pdf=|usr=009}}
| + | |
| − | {{tp|p=32526511|t=2020. A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32473509|t=2020. Zinc Iodide in combination with Dimethyl Sulfoxide for treatment of SARS-CoV-2 and other viral infections.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32470789|t=2020. Survival of COVID-19 patients requires precise immune regulation: The hypothetical immunoprotective role of nicotinic agonists.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32534175|t=2020. Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32464494|t=2020. Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32526507|t=2020. Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32464493|t=2020. Hypoxia inducible factor-1 protects against COVID-19: A hypothesis.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32464492|t=2020. Can moderate intensity aerobic exercise be an effective and valuable therapy in preventing and controlling the pandemic of COVID-19?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32460208|t=2020. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32425307|t=2020. Mesenchymal Stem Cells -Bridge Catalyst Between Innte And Adaptive Immunity In Covid 19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32425306|t=2020. Protective potential of Expectorants against COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32416408|t=2020. As a potential treatment of COVID-19: Montelukast.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32413699|t=2020. Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32531538|t=2020. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32531537|t=2020. RAGE receptor: May be a potential inflammatory mediator for SARS-COV-2 infection?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32516733|t=2020. B-cell engineering: A promising approach towards vaccine development for COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32535456|t=2020. Natural RNA dependent RNA polymerase inhibitors: Molecular docking studies of some biologically active alkaloids of Argemone mexicana.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32534337|t=2020. Diacerein: A potential multi-target therapeutic drug for COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32505075|t=2020. Fighting against frailty and sarcopenia - As well as COVID-19?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32505072|t=2020. COVID-19 and picotechnology: Potential opportunities.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32505069|t=2020. Hydrogen peroxide and viral infections: A literature review with research hypothesis definition in relation to the current covid-19 pandemic.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32400020|t=2020. COVID-19 and implications for thiopurine use.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32395220|t=2020. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32470350|t=2020. Commentary: Myths and facts on vitamin D amidst the COVID-19 pandemic.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32497535|t=2020. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32418885|t=2020. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32473390|t=2020. A review of South Indian medicinal plant has the ability to combat against deadly viruses along with COVID-19?|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32445881|t=2020. Arbidol/IFN-alpha2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32442649|t=2020. Plant Solutions for the COVID-19 Pandemic and Beyond: Historical Reflections and Future Perspectives.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32404512|t=2020. Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32445439|t=2020. Surgery Scheduling in a Crisis.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32529545|t=2020. Natural Products as Potential Leads Against Coronaviruses: Could They be Encouraging Structural Models Against SARS-CoV-2?|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32533109|t=2020. Passive antibody therapy in COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32393823|t=2020. BCG-induced trained immunity: can it offer protection against COVID-19?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32462282|t=2020. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32451597|t=2020. Vitamin D can prevent COVID-19 infection-induced multiple organ damage.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32430617|t=2020. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32342609|t=2020. The Use of Non-invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID-19: A Theoretical Hypothesis and Early Clinical Experience.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32383751|t=2020. Beyond Smoking Cessation: Investigating Medicinal Nicotine to Prevent and Treat COVID-19.|pdf=|usr=009
| + | |
| − | {{tp|p=32521760|t=2020. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32532069|t=2020. Can Probiotics and Diet Promote Beneficial Immune Modulation and Purine Control in Coronavirus Infection?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32519174|t=2020. What can we learn about corticosteroid therapy as a treatment for COVID-19?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32528623|t=2020. COVID-19 infection and oxidative stress: an under-explored approach for prevention and treatment?|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32431755|t=2020. The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32451736|t=2020. Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32454586|t=2020. Demand for potentially hazardous COVID-19 treatments.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32454583|t=2020. ICER releases pricing models for potential COVID-19 treatments.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32473310|t=2020. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32445955|t=2020. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32430287|t=2020. Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32405226|t=2020. Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32502640|t=2020. Optimising effectiveness of health care and value of clinical trials in the COVID -19 outbreak.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32470470|t=2020. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32442437|t=2020. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32437972|t=2020. COVID-19: Beyond the virus. The use of Photodynamic Therapy for the Treatment of Infections in the Respiratory Tract.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32493609|t=2020. SGLT-2 inhibitors for COVID-19 - A miracle waiting to happen or just another beat around the bush?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32519302|t=2020. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32415971|t=2020. Use of statins in patients with COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32415962|t=2020. Reply: Use of statins in patients with COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32522574|t=2020. Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32514354|t=2020. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32426002|t=2020. Opciones Terapeuticas En El Manejo De Covid-19 Grave: Una Perspectiva De Reumatologia.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32426001|t=2020. Colchicina: una herramienta terapeutica potencial frente a COVID-19. Experiencia en 5 pacientes.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32414660|t=2020. Exercising in times of COVID-19: what do experts recommend doing within four walls?|pdf=|usr=009}}
| + | |
| − | {{tp|p=32491104|t=2020. Clinical characteristics and therapeutic procedure for a critical case of novel coronavirus pneumonia treated with glucocorticoids and non-invasive ventilator treatment.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32404477|t=2020. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32467561|t=2020. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32460839|t=2020. Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32526079|t=2020. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32412544|t=2020. In silico fight against novel coronavirus by finding chromone derivatives as inhibitor of coronavirus main proteases enzyme.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32436460|t=2020. TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32436445|t=2020. Potential specific therapies in COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32483428|t=2020. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32487513|t=2020. Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32532691|t=2020. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32467007|t=2020. Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32425645|t=2020. Use of convalescent plasma in COVID-19 patients in China.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32406985|t=2020. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32471655|t=2020. Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32454984|t=2020. Battling COVID-19: using old weapons for a new enemy.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32376108|t=2020. Archetype analysis of older adult immunization decision-making and implementation in 34 countries.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32236815|t=2020. Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | {{tp|p=32530808|t=2020. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32531236|t=2020. Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32532094|t=2020. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32532085|t=2020. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).|pdf=|usr=009}}
| + | |
| − | {{tp|p=32426090|t=2020. COVID-19, asthma, and biologic therapies: What we need to know.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32417996|t=2020. BCG versus COVID-19: impact on urology.|pdf=|usr=009}}
| + | |
| − | {{tp|p=32514854|t=2020. Biologikatherapie nach COVID-19-Infektion : Keine Reaktivierung einer COVID-19-Infektion bei positivem Antikorperstatus SARS-CoV-2 unter Biologikatherapie.|pdf=|usr=009}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32555446|t=2020. Overview of therapeutic drug research for COVID-19 in China.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32574894|t=2020. Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32583087|t=2020. IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32543882|t=2020. Promoting Better Clinical Trials and Drug Information as Public Health Interventions for the COVID-19 Emergency in Italy.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32571831|t=2020. IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32575554|t=2020. Targeting the Heme-Heme Oxygenase System to Prevent Severe Complications Following COVID-19 Infections.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32562705|t=2020. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32557214|t=2020. Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32586336|t=2020. A prospect on the use of antiviral drugs to control local outbreaks of COVID-19.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32572174|t=2020. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32546835|t=2020. Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32492407|t=2020. Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32546764|t=2020. Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32541865|t=2020. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32588163|t=2020. Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32585295|t=2020. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32564213|t=2020. The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32564212|t=2020. Comment on "Colchicine may not be effective in COVID-19 infection; it may even be harmful?"|pdf=|usr=010}}
| + | |
| − | {{tp|p=32556936|t=2020. Colchicine as a possible therapeutic option in COVID-19 infection.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32548723|t=2020. Impact of anti-rheumatic drugs and steroids on clinical course and prognosis of COVID-19.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32593060|t=2020. Helping doctors hasten COVID-19 treatment: Towards a rescue framework for the transfusion of best convalescent plasma to the most critical patients based on biological requirements via ml and novel MCDM methods.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32558354|t=2020. Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32552848|t=2020. Compassionate use of others' immunity - understanding gut microbiome in Covid-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32552832|t=2020. First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32572376|t=2020. Literature-based review of the drugs used for the treatment of COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32578027|t=2020. A Rapid Advice Guideline for the Prevention of Novel Coronavirus Through Nutritional Intervention.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32562159|t=2020. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32542964|t=2020. Treatment of Covid19 - Repurposing drugs commonly used in dermatology.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32537890|t=2020. Observation and consideration on using of JAKi in clinical trials in times of COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32592841|t=2020. A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32581194|t=2020. Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?|pdf=|usr=010}}
| + | |
| − | {{tp|p=32554953|t=2020. Can mesenchymal stem cell therapy be the interim management of COVID-19?|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32574699|t=2020. Discovering small-molecule therapeutics against SARS-CoV-2.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32574697|t=2020. Current and future therapeutical approaches for COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32569833|t=2020. Exportin 1 inhibition as antiviral therapy.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32546018|t=2020. The broad-spectrum antiviral recommendations for drug discovery against COVID-19.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32592145|t=2020. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32574958|t=2020. Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32573433|t=2020. Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32569446|t=2020. Can artificial intelligence identify effective COVID-19 therapies?|pdf=|usr=010}}
| + | |
| − | {{tp|p=32579067|t=2020. In Vivo Expressed Biologics for Infectious Disease Prophylaxis: Rapid Delivery of DNA-Based Antiviral Antibodies.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32562594|t=2020. Pregnant Women in Trials of COVID-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32561291|t=2020. Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?|pdf=|usr=010}}
| + | |
| − | {{tp|p=32554535|t=2020. Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors (nAChR) and beyond.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32589055|t=2020. Vesicular drug-delivery systems as theranostics in COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32564623|t=2020. Tackling SARS-CoV-2: proposed targets and repurposed drugs.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32578073|t=2020. Elderly at time of COronaVIrus disease 2019 (COVID-19): possible role of immunosenescence and malnutrition.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32577840|t=2020. Introduction: microbes, networks, knowledge-disease ecology and emerging infectious diseases in time of COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32544304|t=2020. Antiretroviral HIV drugs in COVID-19 research: promises and risks. An opinion piece.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32591003|t=2020. Application of CRISPR/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32546029|t=2020. Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32588335|t=2020. COVID-19, equipoise and observational studies: a reminder of forgotten issues.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32557206|t=2020. Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32582401|t=2020. Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32582400|t=2020. Steps towards COVID-19 suppression.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32585284|t=2020. Therapeutic Plasma Exchange in Adults with Severe COVID-19 Infection.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32579907|t=2020. Paromomycin: a potential dual targeted drug effectively inhibits both Spike (S1) and Main Protease of COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32585194|t=2020. Convalescent plasma therapy in the treatment of COVID-19: Some considerations: Correspondence.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32592113|t=2020. Potential role of incretins in diabetes and COVID-19 infection: a hypothesis worth exploring.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32588377|t=2020. Corticosteroids in diabetes patients infected with COVID-19.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32578215|t=2020. Could Anti-Tubercular Vaccination Protect Against Covid-19 Infection?|pdf=|usr=010}}
| + | |
| − | {{tp|p=32552021|t=2020. From "Infodemics" to Health Promotion: A Novel Framework for the Role of Social Media in Public Health.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32579022|t=2020. Lung Mechanics in COVID-19 Resemble RDS not ARDS: Could Surfactant be a Treatment?|pdf=|usr=010}}
| + | |
| − | {{tp|p=32579020|t=2020. Treatment of COVID-19 by Inhaled NO to Reduce Shunt?|pdf=|usr=010}}
| + | |
| − | {{tp|p=32551560|t=2020. Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32585180|t=2020. Use of inhaled corticosteroids in asthma and COVID-19 : Keep calm and carry on.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32561608|t=2020. Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32574109|t=2020. Structural Basis of the SARS-CoV-2/SARS-CoV Receptor Binding and Small-Molecule Blockers as Potential Therapeutics.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32551883|t=2020. COVID-19 and the Drug Repurposing Tsunami.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32573724|t=2020. Improved Clinical Symptoms and Mortality on Severe/Critical COVID-19 Patients Utilizing Convalescent Plasma Transfusion.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32559767|t=2020. Use of Convalescent Plasma in Hospitalized Patients with Covid-19 - Case Series.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32576548|t=2020. Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32546467|t=2020. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32548616|t=2020. Corticosteroids in patients with COVID-19: what about the control group?|pdf=|usr=010}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32584431|t=2020. Colchicin Treatment of Covid-19 Presenting With Cutaneous Rash and Myopericarditis.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32562762|t=2020. SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32588937|t=2020. Adjustments in analyses of vitamin D status, allowing for vitamin D determinants, for Covid-19 risks.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32559771|t=2020. The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32588530|t=2020. RNA to the rescue: RNA is one of the most promising targets for drug development given its wide variety of uses.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32567239|t=2020. Advantages of Using Lotteries to Select Participants for High-Demand Covid-19 Treatment Trials.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32574081|t=2020. Can nanotechnology help in the fight against COVID-19?|pdf=|usr=010}}
| + | |
| − | {{tp|p=32552044|t=2020. Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32576053|t=2020. Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32553760|t=2020. TNFalpha-antagonist use and mucosal inflammation are associated with increased intestinal expression of SARS-CoV-2 host protease TMPRSS2 in patients with inflammatory bowel disease.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32553757|t=2020. Aminosalicylates and COVID-19: Facts or Coincidences?|pdf=|usr=010}}
| + | |
| − | {{tp|p=32554621|t=2020. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32557541|t=2020. A Comprehensive Review on Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32561274|t=2020. In silico prediction of potential inhibitors for the Main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32539378|t=2020. Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32562701|t=2020. Apelin-potential therapy for COVID-19?|pdf=|usr=010}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32543196|t=2020. Repositioning of 8565 Existing Drugs for COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32586380|t=2020. Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19).|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32589146|t=2020. Statistical Issues and Lessons Learned from COVID-19 Clinical Trials with Lopinavir-Ritonavir and Remdesivir.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32553190|t=2020. Appropriate selection of convalescent plasma donors for COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32555367|t=2020. Regional BCG vaccination policy in former East- and West Germany may impact on both severity of SARS-CoV-2 and incidence of childhood leukemia.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32555296|t=2020. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32561657|t=2020. Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?|pdf=|usr=010}}
| + | |
| − | {{tp|p=32590324|t=2020. Targeting adenosinergic pathway and adenosine A2A receptor signaling for the treatment of COVID-19: A hypothesis.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32575019|t=2020. Pirfenidone: A novel hypothetical treatment for COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32558640|t=2020. Cibler la protease majeure du SARS-CoV-2 pour fabriquer un medicament efficace contre ce coronavirus.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32590819|t=2020. Critically ill patients with COVID-19 with ECMO and artificial liver plasma exchange: A retrospective study.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32574789|t=2020. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).|pdf=|usr=010}}
| + | |
| − | {{tp|p=32570850|t=2020. Microbiota Modulating Nutritional Approaches to Countering the Effects of Viral Respiratory Infections Including SARS-CoV-2 through Promoting Metabolic and Immune Fitness with Probiotics and Plant Bioactives.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32546125|t=2020. Erythropoietin as candidate for supportive treatment of severe COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32560203|t=2020. Quinoxaline Derivatives as Antiviral Agents: A Systematic Review.|pdf=|usr=010}}
| + | |
| − | {{ttp|p=32551679|t=2020. Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32557405|t=2020. Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32576980|t=2020. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32587103|t=2020. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?|pdf=|usr=010}}
| + | |
| − | {{tp|p=32590117|t=2020. Nitric oxide dosed in short bursts at high concentrations may protect against Covid 19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32405159|t=2020. May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?|pdf=|usr=010}}
| + | |
| − | {{tp|p=32564413|t=2020. Is 0.5% Hydrogen Peroxide Effective against SARS-CoV-2?|pdf=|usr=010}}
| + | |
| − | {{tp|p=32587806|t=2020. A potential role for Galectin-3 inhibitors in the treatment of COVID-19.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32565309|t=2020. Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32592716|t=2020. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?|pdf=|usr=010}}
| + | |
| − | {{tp|p=32562826|t=2020. Therapeutic potential of resveratrol against emerging respiratory viral infections.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32542785|t=2020. Baricitinib: A review of pharmacology, safety and emerging clinical experience in COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32592911|t=2020. Does photodynamic therapy have potential in the treatment of COVID 19 patients?|pdf=|usr=010}}
| + | |
| − | {{tp|p=32585401|t=2020. Optical theranostics and treatment dosimetry for COVID-19 lung complications: towards increasing the survival rate of vulnerable populations.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32585400|t=2020. Ultraviolet-based biophotonic technologies for control and prevention of COVID-19, SARS and related disorders.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32570995|t=2020. Short-Term Dexamethasone in Sars-CoV-2 Patients.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32552811|t=2020. E-cigarette-induced pulmonary inflammation and dysregulated repair are mediated by nAChR alpha7 receptor: role of nAChR alpha7 in SARS-CoV-2 Covid-19 ACE2 receptor regulation.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32558034|t=2020. National policies for paediatric universal BCG vaccination were associated with decreased mortality due to COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32557955|t=2020. Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32571730|t=2020. Anakinra, una alternativa potencial en el tratamiento de la infeccion respiratoria grave por SARS-CoV-2 refractaria a tocilizumab.|pdf=|usr=010}}
| + | |
| − | {{ttp|p=32579014|t=2020. Systemic inflammatory response and thrombosis due to alterations in the gut microbiota in COVID-19.|pdf=|usr=010}}
| + | |
| − | {{ttp|p=32579012|t=2020. COVID-19. Immunothrombosis and the gastrointestinal tract.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32568026|t=2020. Targeting infectious Coronavirus Disease 2019 (COVID-19) with Artificial Intelligence (AI) applications: Evidence based opinion.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32593196|t=2020. The Another Side of COVID-19 in Alzheimer's Disease Patients: Drug-Drug Interactions.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32591771|t=2020. The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32586154|t=2020. Montelukast's ability to fight COVID-19 infection.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32583729|t=2020. Immunoinformatics study to search epitopes of spike glycoprotein from SARS-CoV-2 as potential vaccine.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32579065|t=2020. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32579061|t=2020. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL(pro).|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32573355|t=2020. Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32571168|t=2020. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32568618|t=2020. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32568613|t=2020. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an in silico docking and molecular dynamics simulation study.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32568013|t=2020. Virtual screening and dynamics of potential inhibitors targeting RNA binding domain of nucleocapsid phosphoprotein from SARS-CoV-2.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32568012|t=2020. Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32567995|t=2020. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32567989|t=2020. In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32567979|t=2020. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32567501|t=2020. Constituents of buriti oil (Mauritia flexuosa L.) like inhibitors of the SARS-Coronavirus main peptidase: an investigation by docking and molecular dynamics.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32567487|t=2020. nCOV-19 peptides mass fingerprinting identification, binding, and blocking of inhibitors flavonoids and anthraquinone of Moringa oleifera and hydroxychloroquine.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32568969|t=2020. Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32579707|t=2020. Clinical pharmacology considerations for developing small molecule treatments for COVID-19.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32584243|t=2020. Empiric Therapies for COVID-19: Destined to Fail by Ignoring the Lessons of History.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32591393|t=2020. A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32559419|t=2020. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32574572|t=2020. Letter to the editor: Immunomodulation by phsphodiesterase-4 inhibitor in COVID-19 patients.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32579258|t=2020. Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32578354|t=2020. Obesity and COVID-19: The mTOR pathway as a possible culprit.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32588453|t=2020. Covid-19 and Thymoquinone: Connecting the Dots.|pdf=|usr=010}}
| + | |
| − | {{ttp|p=32552307|t=2020. A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32569363|t=2020. Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab - A Case- Controlled Study.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32584474|t=2020. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32568376|t=2020. Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32556278|t=2020. Real-life experience of tocilizumab use in COVID-19 patients.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32543892|t=2020. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32590699|t=2020. ACTH 1-24 and other melanocortins for COVID-19 treatment.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32573990|t=2020. Heart Transplant Recipient Patient with COVID-19 Treated with Tocilizumab.|pdf=|usr=010}}
| + | |
| − | {{tp|p=32584762|t=2020. [Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].|pdf=|usr=010}}
| + | |
| − | | + | |
| − | {{tp|p=32542847|t=2020. Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities.|pdf=|usr=010}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32547694|t=2020. Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32547693|t=2020. A Role for Metal-Based Drugs in Fighting COVID-19 Infection? The Case of Auranofin.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32599103|t=2020. COVID-19 Fatalities, Latitude, Sunlight, and Vitamin D.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32593520|t=2020. Tocilizumab en nino con leucemia linfoblastica aguda y sindrome de liberacion de citoquinas asociado a COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32566569|t=2020. Appealing for efficient, well organized clinical trials on COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32566564|t=2020. Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32566562|t=2020. Effectiveness of intravenous immunoglobulin for children with severe COVID-19: a rapid review.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32566561|t=2020. Potential effectiveness and safety of antiviral agents in children with coronavirus disease 2019: a rapid review and meta-analysis.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32566896|t=2020. Perspectives on the development of neutralizing antibodies against SARS-CoV-2.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32545171|t=2020. Antimicrobial Photodynamic Therapy in the Control of COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32545518|t=2020. Nrf2 Activator PB125((R)) as a Potential Therapeutic Agent against COVID-19.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32536457|t=2020. Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32546446|t=2020. Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32594322|t=2020. Antiviral activity of berberine.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32593613|t=2020. Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32571182|t=2020. Molecular Targets in the Chemotherapy of Coronavirus Infection.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32563698|t=2020. Repurposing old drugs as antiviral agents for coronaviruses.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32599963|t=2020. Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32536632|t=2020. Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32459144|t=2020. Discovery of alliin as a putative inhibitor of the main protease of SARS-CoV-2 by molecular docking.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32420049|t=2020. Combating COVID-19 with Mesenchymal Stem Cell therapy.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32493331|t=2020. An evidence mapping and analysis of registered COVID-19 clinical trials in China.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32518212|t=2020. Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32532425|t=2020. Inclusion of pregnant women in clinical trials of COVID-19 therapies: what have we learned?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32557557|t=2020. Harnessing resolving-based therapeutics to treat pulmonary viral infections: What can the future offer to COVID-19?|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32571773|t=2020. Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32407543|t=2020. Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID-19 infected patients.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32562276|t=2020. Statins: Could an old friend help the fight against COVID-19?|pdf=|usr=011}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32397275|t=2020. Potential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinson's Disease.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32603679|t=2020. Calcineurin inhibitors revisited: A new paradigm for COVID-19?|pdf=|usr=011}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32383125|t=2020. Prophylaxie post-exposition ou traitement preventif pour le syndrome respiratoire aigu severe du coronavirus 2 (SARS-CoV-2) : protocole d'etude pour une etude randomisee controlee pragmatique.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32394335|t=2020. Corticosteroids for critically ill COVID-19 patients with cytokine release syndrome: a limited case series.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32385712|t=2020. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32389579|t=2020. Irradiation pulmonaire a faible dose pour l'orage de cytokines du COVID-19 : pourquoi pas ?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32599589|t=2020. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32426243|t=2020. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32531248|t=2020. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32547788|t=2020. Off-label therapy targeting pathogenic inflammation in COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32411313|t=2020. FAVORABLE ANAKINRA RESPONSES IN SEVERE COVID-19 PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32464097|t=2020. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32413276|t=2020. Identification of Human Single-Domain Antibodies against SARS-CoV-2.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32610043|t=2020. Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32606347|t=2020. Distinct stem/progenitor cells proliferate to regenerate the trachea, intrapulmonary airways and alveoli in COVID-19 patients.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32409956|t=2020. Possible application of H2S-producing compounds in therapy of coronavirus (COVID-19) infection and pneumonia.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32606050|t=2020. COVID-19 treatment: Combining anti-inflammatory and antiviral therapeutics using a network-based approach.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32599278|t=2020. Imatinib for COVID-19: A case report.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32603802|t=2020. Corticosteroid administration for viral pneumonia: COVID-19 and beyond.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32610262|t=2020. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32601778|t=2020. Repurposed GI Drugs in the Treatment of COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32593662|t=2020. Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32607779|t=2020. Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32594204|t=2020. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32603692|t=2020. Current pharmacological treatments for SARS-COV-2: A narrative review.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32598953|t=2020. Drug treatment of coronavirus disease 2019 (COVID-19) in China.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32598985|t=2020. Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32594820|t=2020. Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32606823|t=2020. Potential Role of Nrf2 Activators with Dual Antiviral and Anti-Inflammatory Properties in the Management of Viral Pneumonia.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32610153|t=2020. COVID-19 trials in Italy: A call for simplicity, top standards and global pooling.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574504|t=2020. Metabolomics to Predict Antiviral Drug Efficacy in COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32597948|t=2020. Predicting Human Microbe-Drug Associations via Graph Convolutional Network with Conditional Random Field.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32593183|t=2020. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32593180|t=2020. Convalescent plasma for persisting Covid-19 following therapeutic lymphocyte depletion: a report of rapid recovery.|pdf=|usr=011}}
| + | |
| − | {{ttp|p=32584421|t=2020. Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32584416|t=2020. Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32536693|t=2020. Antiviral Therapy during the Coronavirus Disease (COVID-19) Pandemic: Is It Appropriate to Treat Patients in the Absence of Significant Evidence?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32538775|t=2020. Combating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor-kappab pathways in non-pregnant and pregnant populations.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32553536|t=2020. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized COVID-19 Patients: Survival and Clinical Outcomes.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32573419|t=2020. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32597466|t=2020. Use of Baricitinib in Patients with Moderate and Severe COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32594142|t=2020. COVID-19 pharmacologic treatments for children: research priorities and approach to pediatric studies.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32594120|t=2020. Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with P-glycoprotein inhibitors.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32588877|t=2020. High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32585016|t=2020. THE RIGHT TIME FOR STEROIDS IN COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32575124|t=2020. Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32604407|t=2020. Immune modulation in COVID-19: Strategic considerations for personalized therapeutic intervention.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32602952|t=2020. Convalescent Plasma Therapy: Helpful Treatment of COVID-19 in a Kidney Transplant Recipient presenting with serve clinical manifestation and complex complications.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32538717|t=2020. Structural Biology Aids the Research of New Anti-COVID-19 Drugs.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32536564|t=2020. IL-15 immunotherapy is a viable strategy for COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32540737|t=2020. Use of pioglitazone in people with type 2 diabetes mellitus with coronavirus disease 2019 (COVID-19): Boon or bane?|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32538209|t=2020. Possible therapeutic agents for COVID-19: a comprehensive review.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32603486|t=2020. Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32603297|t=2020. Systematic Review and Meta-Analysis of the Efficacy of Nanoscale Materials Against Coronaviruses-Possible Potential Antiviral Agents for SARS-CoV-2.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32603531|t=2020. Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32603576|t=2020. Vitamin D and Inflammation: Potential Implications for Severity of Covid-19.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32518817|t=2020. Synthesis, Spectroscopic Characterizations of Novel Norcantharimides, Their ADME Properties and Docking Studies Against COVID-19 M(pr) degrees .|pdf=|usr=011}}
| + | |
| − | {{tp|p=32572383|t=2020. Evaluation of the Inhibitory Activities of COVID-19 of Melaleuca cajuputi Oil Using Docking Simulation.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32548601|t=2020. Ventilation in the Dental Clinic: An Effective Measure to Control Droplets and Aerosols during the Coronavirus Pandemic and Beyond.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32548600|t=2020. Preventive and Control Measures for the Coronavirus Pandemic in Clinical Dentistry.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32242749|t=2020. Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARS-CoV-2 Infection?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32513807|t=2020. What is the role of supplementation with ascorbic acid, zinc, vitamin D, or N-acetylcysteine for prevention or treatment of COVID-19?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32533455|t=2020. Azithromycin for COVID-19: More Than Just an Antimicrobial?|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32492478|t=2020. Treating COVID-19 with colchicine in community healthcare setting.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32544611|t=2020. Development of child immunity in the context of COVID-19 pandemic.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32418917|t=2020. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!|pdf=|usr=011}}
| + | |
| − | {{tp|p=32417594|t=2020. Supplements for COVID-19: A modifiable environmental risk.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32405269|t=2020. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32409832|t=2020. SARS-CoV-2 pandemic : Time to revive the cyclophilin inhibitor alisporivir.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32537133|t=2020. Potential Treatments for SARS-CoV-2 Infection.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32454187|t=2020. Review of trials currently testing treatment and prevention of COVID-19.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32407539|t=2020. Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32311763|t=2020. Off-Label Therapies for COVID-19-Are We All In This Together?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32451729|t=2020. Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32394215|t=2020. Colchicine may not be effective in COVID-19 infection; it may even be harmful?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32388748|t=2020. Reply to Rheumatologists' perspective on coronavirus disease 19: is heparin the dark horse for COVID-19?|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32575032|t=2020. Participation of more community hospitals in randomized trials of treatments for COVID-19 is needed.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32493740|t=2020. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARSCoV-2 and other acute viral infections: a systematic review and meta-analysis.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32392494|t=2020. Sample sizes in COVID-19-related research.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32485652|t=2020. Interaction of the prototypical alpha-ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: Molecular dynamic simulations highlight the stability of the ligand-protein complex.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32537526|t=2020. The critical role of futility analysis in the pursuit of effective treatments for COVID-19.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32384906|t=2020. Use of triiodothyronine to treat critically ill COVID-19 patients: a new clinical trial.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32430057|t=2020. Adjuvant corticosteroid therapy for critically ill patients with COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32414417|t=2020. Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32513242|t=2020. Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32513225|t=2020. Neutrophil Elastase Inhibitors: A potential prophylactic treatment option for SARS-CoV-2-induced respiratory complications?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32487260|t=2020. Precision medicine for COVID-19: a call for better clinical trials.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32487139|t=2020. Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32532353|t=2020. Interferon beta-1a for COVID-19: critical importance of the administration route.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32527304|t=2020. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32544802|t=2020. COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32460133|t=2020. Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32494546|t=2020. Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32596078|t=2020. Emerging Pharmaceutical Treatments of Novel COVID-19: A Review.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32577324|t=2020. COVID-19: A Review of Emerging Preventative Vaccines and Treatment Strategies.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32550078|t=2020. Heated Air Delivery by Micro-Sauna: An Experimental Treatment Prototype Concept for Coronavirus Disease 2019.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32540367|t=2020. A review of potential treatments to date in COVID-19 patients according to the stage of the disease.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32563554|t=2020. Should we unstress SARS-CoV-2 infected cells?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32565132|t=2020. Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32563941|t=2020. Letter in response to the article: Vitamin D concentrations and COVID-19 infection in UK biobank (Hastie et al.).|pdf=|usr=011}}
| + | |
| − | {{tp|p=32593491|t=2020. Molecular pharmacology of ciclesonide against SARS-CoV-2.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32607505|t=2020. COVID-19 Clinical Research.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32605278|t=2020. Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32605780|t=2020. Role of vitamin D in preventing of COVID-19 infection, progression and severity.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32605149|t=2020. Bioactive Indolyl Diketopiperazines from the Marine Derived Endophytic Aspergillus versicolor DY180635.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32593831|t=2020. Plausible role of combination of Chlorpromazine hydrochloride and Teicoplanin against COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32604775|t=2020. A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32593740|t=2020. Irisin modulates genes associated with severe coronavirus disease (COVID-19) outcome in human subcutaneous adipocytes.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32602074|t=2020. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32603575|t=2020. Vitamin D Deficiency and ARDS after SARS-CoV-2 Infection.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32603574|t=2020. Vitamin D and Covid-19: A Note of Caution.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32603573|t=2020. Covid-19, Cocooning and Vitamin D Intake Requirements.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32551464|t=2020. Dexamethasone for COVID-19? Not so fast.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32597315|t=2020. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32608329|t=2020. In silico analysis and identification of promising hits against 2019 novel coronavirus 3C-like main protease enzyme.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32520770|t=2020. Overview of Coronavirus Disease 2019 (COVID-19): Treatment Updates and Advances.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32530870|t=2020. Rapid Review: Nonsteroidal Anti-inflammatory Agents and Aminosalicylates in COVID-19 Infections.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32570043|t=2020. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574020|t=2020. Biologics and Small Molecules in the Treatment of COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32559285|t=2020. Interferon-beta 1a inhibits SARS-CoV-2 in vitro when administered after virus infection.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32603493|t=2020. Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: An observational study.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32583447|t=2020. SARS-COV-2 and biomimetics: What saves the planet will save our health.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32579254|t=2020. SARS-CoV-2 and SARS-CoV: Virtual Screening of Potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12).|pdf=|usr=011}}
| + | |
| − | {{tp|p=32568411|t=2020. Tocilizumab's efficacy in patients with Coronavirus Disease 2019 (COVID-19) is determined by the presence of cytokine storm.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574379|t=2020. A sugar-coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD-19: An Editorial Highlight for "Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer"on https://doi.org/10.1111/jnc.15021.|pdf=|usr=011}}
| + | |
| − | {{ttp|p=32597503|t=2020. Melatonin Restores Neutrophil Functions and Prevents Apoptosis amid Dysfunctional Glutathione Redox System.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32543164|t=2020. The comparison of the effectiveness of lincocin(R) and azitro(R) in the treatment of covid-19-associated pneumonia: A prospective study.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32608097|t=2020. Comparison of In Vitro Inactivation of SARS CoV-2 with Hydrogen Peroxide and Povidone-Iodine Oral Antiseptic Rinses.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32568282|t=2020. Emerging pharmacotherapy for COVID-19.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32515802|t=2020. Existing Drugs Might Treat COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32539093|t=2020. Monoclonal Antibodies for Prevention and Treatment of COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32544372|t=2020. Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32541129|t=2020. Intermittent high dosage oxygen treats COVID-19 infection: the Chinese studies.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32541128|t=2020. Hyperbaric oxygen treatment of novel coronavirus (COVID-19) respiratory failure.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32594562|t=2020. Clinical trials for the prevention and treatment of COVID-19: current state of play.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32447665|t=2020. Mit IL-6-Inhibitor gegen COVID-19 : Corona-Pandemie.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32342366|t=2020. Autophagie - ein Ansatzpunkt fur ein Medikament gegen COVID-19? : Kampf gegen das Coronavirus.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32581514|t=2020. Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32524646|t=2020. Lithium as a candidate treatment for COVID-19: Promises and pitfalls.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32425222|t=2020. Repurposing chlorpromazine to treat COVID-19: The reCoVery study.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32482571|t=2020. Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32544799|t=2020. Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32563814|t=2020. Fight against novel coronavirus: A perspective of medicinal chemists.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32563813|t=2020. Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32525005|t=2020. Effective block by pirfenidone, an antifibrotic pyridone compound (5-methyl-1-phenylpyridin-2[H-1]-one), on hyperpolarization-activated cation current: An additional but distinctive target.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32563675|t=2020. Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32536989|t=2020. IgY - turning the page toward passive immunization in COVID-19 infection (Review).|pdf=|usr=011}}
| + | |
| − | {{tp|p=32536988|t=2020. [Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32537481|t=2020. EML webinar overview: Simulation-assisted discovery of membrane targeting nanomedicine.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32399192|t=2020. Recent advances in influenza vaccines.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574317|t=2020. Can Stem Cells Beat COVID-19: Advancing Stem Cells and Extracellular Vesicles Toward Mainstream Medicine for Lung Injuries Associated With SARS-CoV-2 Infections.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32596244|t=2020. The Inhibitory Effect of Curcumin on Virus-Induced Cytokine Storm and Its Potential Use in the Associated Severe Pneumonia.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32595653|t=2020. Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32582221|t=2020. Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574274|t=2020. Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574273|t=2020. Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574268|t=2020. Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574267|t=2020. COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574263|t=2020. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574262|t=2020. Interferon-alpha2b Treatment for COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574259|t=2020. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574258|t=2020. Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32582742|t=2020. The Use of Microbial Accessible and Fermentable Carbohydrates and/or Butyrate as Supportive Treatment for Patients With Coronavirus SARS-CoV-2 Infection.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32574339|t=2020. Lung Surfactant for Pulmonary Barrier Restoration in Patients With COVID-19 Pneumonia.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574332|t=2020. Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574331|t=2020. May Polyphenols Have a Role Against Coronavirus Infection? An Overview of in vitro Evidence.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574327|t=2020. Therapeutic Algorithm for Use of Melatonin in Patients With COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574320|t=2020. Doxycycline: From Ocular Rosacea to COVID-19 Anosmia. New Insight Into the Coronavirus Outbreak.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32582138|t=2020. Intestinal Flora as a Potential Strategy to Fight SARS-CoV-2 Infection.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32582137|t=2020. Biosurfactants: A Covid-19 Perspective.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32582134|t=2020. Main Clinical Features of COVID-19 and Potential Prognostic and Therapeutic Value of the Microbiota in SARS-CoV-2 Infections.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32582766|t=2020. Does Early Childhood Vaccination Protect Against COVID-19?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32581810|t=2020. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32581809|t=2020. Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574238|t=2020. An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?|pdf=|usr=011}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32574290|t=2020. Using Probiotics to Flatten the Curve of Coronavirus Disease COVID-2019 Pandemic.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574289|t=2020. Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32547908|t=2020. Ultraviolet irradiation doses for coronavirus inactivation - review and analysis of coronavirus photoinactivation studies.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32566483|t=2020. Doxycycline as a potential partner of COVID-19 therapies.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32546458|t=2020. Covid-19 chemoprophylaxis: Ethics of prevention based on anecdotal evidence.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32540428|t=2020. Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32537482|t=2020. Screening and druggability analysis of some plant metabolites against SARS-CoV-2: An integrative computational approach.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32544867|t=2020. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32544570|t=2020. Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon beta-1b.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32534513|t=2020. COVID-19 Pandemic Hemoperfusion Therapy Versus Plasma Exchange Therapy in Intensive Care.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32534509|t=2020. Management of COVID-19 Virus Infection by Convalescent Plasma.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32534505|t=2020. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32558435|t=2020. Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32565398|t=2020. Effects of Micronutrients or Conditional Amino Acids on COVID-19-Related Outcomes: An Evidence Analysis Center Scoping Review.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32587093|t=2020. Inhibition of SARS-CoV-2 by type I and type III interferons.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32552595|t=2020. Natural compounds from Clerodendrum spp. as possible therapeutic candidates against SARS-CoV-2: An in silico investigation.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32552534|t=2020. Identification of a novel dual-target scaffold for 3CLpro and RdRp proteins of SARS-CoV-2 using 3D-similarity search, molecular docking, molecular dynamics and ADMET evaluation.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32552462|t=2020. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32552361|t=2020. Combined drug repurposing and virtual screening strategies with molecular dynamics simulation identified potent inhibitors for SARS-CoV-2 main protease (3CLpro).|pdf=|usr=011}}
| + | |
| − | {{tp|p=32544024|t=2020. An in silico approach for identification of novel inhibitors as potential therapeutics targeting COVID-19 main protease.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32543978|t=2020. Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds in drug trials.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32538276|t=2020. Repurposing cefuroxime for treatment of COVID-19: a scoping review of in silico studies.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32554907|t=2020. Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32603772|t=2020. Targeting inflammation and cytokine storm in COVID-19.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{ttp|p=32600125|t=2020. Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32594863|t=2020. The potential role of nanomedicine on COVID-19 therapeutics.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32593519|t=2020. Regulatory consideration on preparation and clinical use of COVID-19 convalescent plasma.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32605306|t=2020. Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32546811|t=2020. Coronavirus breakthrough: dexamethasone is first drug shown to save lives.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32071447|t=2020. More than 80 clinical trials launch to test coronavirus treatments.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32214238|t=2020. How blood from coronavirus survivors might save lives.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32597513|t=2020. New intrigant possibility for prevention of coronavirus pneumonitis: natural purified polyphenols.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32541085|t=2020. Citokinellenes terapia az uj tipusu koronavirus okozta megbetegedes (COVID-19) kezeleseben - tocilizumab elsokent valo alkalmazasa egy hazai infektologiai osztalyon.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32564002|t=2020. Az elso ket sikeres, convalescens friss fagyasztott plazmaval torteno terapia hazai alkalmazasa intenziv osztalyon kezelt, kritikus allapotu, COVID-19-fertozesben szenvedo betegekben: (A COVID-19-pandemia orvosszakmai kerdesei)|pdf=|usr=011}}
| + | |
| − | {{tp|p=32579049|t=2020. Photobiomodulation: Shining Light on COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32579493|t=2020. Response to: Can Transdermal Photobiomodulation Help Us at the Time of COVID-19?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32579491|t=2020. Author's Response to Ferreira: Can Transdermal Photobiomodulation Help Us at the Time of COVID-19? An Update.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32584322|t=2020. INFUSION OF CONVALESCENT PLASMA IS ASSOCIATED WITH CLINICAL IMPROVEMENT IN CRITICALLY ILL PATIENTS WITH COVID-19: A PILOT STUDY.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32604223|t=2020. Therapeutic Potential of B-1a Cells in COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32553502|t=2020. Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32561113|t=2020. Current treatment approaches for COVID-19 and the clinical value of transfusion-related technologies.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574447|t=2020. HBO2 for COVID-19: Clinical trials at clinicaltrials.gov.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574446|t=2020. UHMS Position Statement: Hyperbaric Oxygen (HBO2) for COVID-19 Patients.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574433|t=2020. Hyperbaric oxygen therapy may be effective to improve hypoxemia in patients with severe COVID-2019 pneumonia: two case reports.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32574432|t=2020. Hyperbaric oxygen as a treatment for COVID-19 infection?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32567972|t=2020. Autophagy and SARS-CoV-2 infection: Apossible smart targeting of the autophagy pathway.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32530282|t=2020. Computational Determination of Potential Inhibitors of SARS-CoV-2 Main Protease.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32539372|t=2020. Fragment Molecular Orbital Based Interaction Analyses on COVID-19 Main Protease - Inhibitor N3 Complex (PDB ID: 6LU7).|pdf=|usr=011}}
| + | |
| − | {{tp|p=32551639|t=2020. Discovery of New Hydroxyethylamine Analogs against 3CL(pro) Protein Target of SARS-CoV-2: Molecular Docking, Molecular Dynamics Simulation, and Structure-Activity Relationship Studies.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32560227|t=2020. Vaccines and Therapies in Development for SARS-CoV-2 Infections.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32524645|t=2020. Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32535939|t=2020. Critical Need for Implementation of Clinical Pharmacology Principles in Developing Drugs for the Treatment or Prevention of COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32557271|t=2020. Possible role of vitamin D in Covid-19 infection in pediatric population.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32551855|t=2020. Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32560382|t=2020. "Monoclonal-Type" Plastic Antibodies for COVID-19 Treatment: What Is the Idea?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32592703|t=2020. Retrospective, multicenter study on the impact of baricitinib in COVID-19 moderate pneumonia.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32579985|t=2020. Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients: Etoposide for severe COVID-19 patients.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32515499|t=2020. Higher levels of IL-6 early after tocilizumab distinguish survivors from non-survivors in COVID-19 pneumonia: a possible indication for deeper targeting IL-6.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32530507|t=2020. Can steroids reverse the severe COVID-19 induced "cytokine storm"?|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32519764|t=2020. Could melatonin be used in COVID-19 patients with laryngopharyngeal reflux disease?|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32454982|t=2020. Amid COVID-19: the importance of developing an positive adverse drug reaction (ADR) and medical device incident (MDI) reporting culture for Global Health and public safety.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32542782|t=2020. SARS-CoV-2 Viral Inactivation Using Low Dose Povidone-Iodine Oral Rinse-Immediate Application for the Prosthodontic Practice.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32582350|t=2020. Herbs that might be effective for the management of COVID-19: A bioinformatics analysis on anti-tyrosine kinase property.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32600410|t=2020. Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32579195|t=2020. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32579190|t=2020. Colchicine for the Treatment of Myocardial Injury in Patients With Coronavirus Disease 2019 (COVID-19)-An Old Drug With New Life?|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32539990|t=2020. A minimal common outcome measure set for COVID-19 clinical research.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32402512|t=2020. A Case of Coronavirus Disease 2019 Treated With Ciclesonide.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32577056|t=2020. The Nrf2 Activator (DMF) and Covid-19: Is there a Possible Role?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32537610|t=2020. Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32563969|t=2020. Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32540604|t=2020. Iodine, a preventive and curative agent in the COVID-19 pandemic?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32562911|t=2020. Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32554324|t=2020. Noradrenergic and serotonergic drugs may have opposing effects on COVID-19 cytokine storm and associated psychological effects.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32540603|t=2020. Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32563970|t=2020. Deceiving SARS-CoV-2 molecular-tropism clues - A combinational contemporary strategy.|pdf=|usr=011}}
| + | |
| − | {{ttp|p=32590321|t=2020. Endothelial progenitor cells and mesenchymal stem cells to overcome vascular deterioration and cytokine storm in critical patients with COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32554149|t=2020. Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32538585|t=2020. Reply to: What we are talking about when we talk of steroid in COVID-19?|pdf=|usr=011}}
| + | |
| − | {{tp|p=32538591|t=2020. Convalescent plasma and covid-19 treatment.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32447695|t=2020. Therapien gegen COVID-19 - ein Update : SARS-CoV-2-Pandemie.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32405836|t=2020. Wie ernahre ich mich am besten in Zeiten der Corona-Pandemie? : COVID-19 und Ernahrungsmedizin.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32545268|t=2020. Potential of Flavonoid-Inspired Phytomedicines against COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32561155|t=2020. Inmunoglobulinas por via intravenosa: una alternativa terapeutica a tener en cuenta en el paciente trasplantado renal con COVID-19.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32550240|t=2020. Azithromycin Should Not Be Used to Treat COVID-19.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32582329|t=2020. How Nutrition can help to fight against COVID-19 Pandemic.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32582320|t=2020. Beyond transmission: Dire need for integration of nutrition interventions in COVID-19 pandemic-response strategies in Developing Countries like Pakistan.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32582873|t=2020. Evaluation of Ultraviolet-C Light for Rapid Decontamination of Airport Security Bins in the Era of SARS-CoV-2.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32566414|t=2020. Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approach.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32578336|t=2020. Buying time: Drug repurposing to treat the host in COVID-19H.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32380821|t=2020. Therapeutic plasma exchange as a rescue therapy in patients with coronavirus disease 2019: a case series.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32383835|t=2020. Acute respiratory distress syndrome and steroids in the shadow of coronavirus disease 2019.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32540682|t=2020. Psychotropics drugs with cationic amphiphilic properties may afford some protection against SARS-CoV-2: A mechanistic hypothesis.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32590235|t=2020. TB infection and BCG vaccination: are we protected from COVID-19?|pdf=|usr=011}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32583654|t=2020. Baricitinib en el tratamiento de infeccion por SARS-CoV-2.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32595974|t=2020. The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32548259|t=2020. Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32601278|t=2020. Numerical evaluation of spray position for improved nasal drug delivery.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32581288|t=2020. Far-UVC light (222 nm) efficiently and safely inactivates airborne human coronaviruses.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32576928|t=2020. DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32571838|t=2020. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32540904|t=2020. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32540903|t=2020. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32540902|t=2020. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32540901|t=2020. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32540900|t=2020. Broad neutralization of SARS-related viruses by human monoclonal antibodies.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32570174|t=2020. SARS-CoV-2 infection and stem cells: Interaction and intervention.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32592163|t=2020. 'Primed' Mesenchymal Stem Cells: a Potential Novel Therapeutic for COVID19 Patients.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32564256|t=2020. Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32577236|t=2020. Preventing SARS-CoV-2 infection by blocking a tissue serine protease.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32539647|t=2020. Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32583289|t=2020. Statistical Evaluation of Clinical Trials Under COVID-19 Pandemic.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32557317|t=2020. New FDA Guidance on General Clinical Trial Conduct in the Era of COVID-19.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32540345|t=2020. Anti-SARS-CoV-2 hyperimmune plasma workflow.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32563550|t=2020. Plasma from donors convalescent from SARS-CoV-2 infection-A matter of priorities.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32359090|t=2020. Convalescent plasma: possible therapy for novel coronavirus disease 2019.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32563584|t=2020. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32580895|t=2020. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.|pdf=|usr=011}}
| + | |
| − | {{ttp|p=32551457|t=2020. Possible Old Drugs for Repositioning in COVID-19 Treatment: Combating Cytokine Storms from Haloperidol to Anti-interleukin Agents.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32551456|t=2020. Use of Spironolactone in SARS-CoV-2 ARDS Patients.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32595362|t=2020. Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32595360|t=2020. Interaction of certain monoterpenoid hydrocarbons with the receptor binding domain of 2019 novel coronavirus (2019-nCoV), transmembrane serine protease 2 (TMPRSS2), cathepsin B, and cathepsin L (CatB/L) and their pharmacokinetic properties.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32595359|t=2020. Potentials of plant-based substance to inhabit and probable cure for the COVID-19.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32595357|t=2020. SARS-CoV-2 neutralizing antibody development strategies.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32595355|t=2020. Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32585913|t=2020. SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32575350|t=2020. Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients.|pdf=|usr=011}}
| + | |
| − | | + | |
| − | {{tp|p=32560646|t=2020. Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32592817|t=2020. Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32569708|t=2020. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32565126|t=2020. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32545799|t=2020. Potential Antiviral Options against SARS-CoV-2 Infection.|pdf=|usr=011}}
| + | |
| − | {{tp|p=32573126|t=2020. Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?|pdf=|usr=011}}
| + | |
